ConvaTec updates its long-term strategy, shares anchored in FTSE 100 healthcare

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 12:32.

ConvaTec (GB00BD3VFW73) shapes a long-term growth narrative in the UK-listed healthcare segment. The company, a constituent of the FTSE 100 on the London Stock Exchange, continues to emphasize chronic care, advanced wound care and infusion therapies in its investor materials.ConvaTec investor information

Long-term strategy in chronic care

ConvaTec outlines a multi-year strategy built around four core franchises: Advanced Wound Care, Ostomy Care, Continence & Critical Care, and Infusion Care, with a focus on recurring revenues from chronic patients.Strategy and results presentations The group highlights demographic trends such as aging populations and rising incidence of diabetes and pressure ulcers as structural demand drivers.

Management presents this strategy in regular capital markets materials, emphasizing disciplined capital allocation to high-return projects and selective bolt-on acquisitions in medical devices.Financial Times coverage of UK healthcare groups The aim is to balance organic growth in key categories with margin expansion through efficiency programs and portfolio focus.

Position in the FTSE 100 peer group

ConvaTec sits in the FTSE 100 alongside larger diversified healthcare names such as Smith & Nephew and GSK, giving investors a clear peer context in terms of valuation and growth expectations.FTSE 100 index composition The company is generally grouped with medical technology and chronic care specialists, rather than big pharma, in sector classifications.

Analyst consensus compiled by MarketScreener shows a mix of Buy and Hold ratings for ConvaTec, with brokers such as UBS and Goldman Sachs covering the stock as part of their UK medtech universe.MarketScreener analyst overview The coverage typically focuses on execution of the long-term plan, margin trajectory and cash generation, rather than short-term trading catalysts.

The products behind the stock

ConvaTec generates most of its revenues from chronic-care products such as the Aquacel advanced wound dressings, which are used in hospitals and community settings to manage complex wounds including diabetic foot ulcers and surgical incisions.Aquacel wound dressing portfolio Additional income stems from ostomy systems, continence devices and infusion sets, giving the group a diversified but focused medical technology portfolio.

Where the shares trade today

The ConvaTec shares (GB00BD3VFW73) trade on the London Stock Exchange, quoted in pounds sterling; the latest live-verified price and timestamp are available on the exchange website and major data providers.

This article is for informational purposes only and does not constitute investment advice, tax advice or a solicitation to buy or sell securities. Data and sources are believed to be reliable but cannot be guaranteed; investors should conduct their own research or consult a professional advisor.